CU-T12-9 NEW
| Price | $48 | $113 | $172 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: CU-T12-9 | CAS No.: 1821387-73-8 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | CU-T12-9 |
| Description | CU-T12-9 is a potent TLR1/2 agonist(EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay). It acts by activating the NFkB pathway, upregulating proinflammatory cytokines, and enhancing TLR1 and TLR2 dimerization.CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS. |
| In vitro | CU-T12-9 directly targets TLR1/2 to initiate downstream signaling. It specifically induces TLR1/2 activation, which can be blocked by either the anti-hTLR1 or anti-hTLR2 antibody, but not the anti-hTLR6 antibody. By binding to both TLR1 and TLR2, CU-T12-9 facilitates TLR1/2 heterodimer formation, activating downstream signaling. Fluorescence anisotropy assays revealed competitive binding to the TLR1/2 complex between CU-T12-9 and Pam3CSK4, with an IC50 of 54.4 nM. CU-T12-9 signals through nuclear factor κB (NF-κB) and elevates downstream effectors tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and inducible nitric oxide synthase (iNOS)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (27.6 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (27.6 mM), Solution. DMSO : 250 mg/mL (690.02 mM), Sonication is recommended. |
| Keywords | Toll-like Receptor (TLR) | TLR2 | TLR1/2 | TLR1 | TLR | specific | pancreatic | obesity | Inhibitor | inhibit | influenza | inflammatory | infectious | diseases | CU-T12-9 | CU-T-12-9 | CUT129 | CU T12 9 | carcinoma | cancer | breast | bladder | asthma |
| Inhibitors Related | D-Glucuronic acid | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloranil | CU-115 | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP |
| Related Compound Libraries | NF-κB Signaling Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Antioxidant Compound Library | Pyroptosis Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY